Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

NCT01107886 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

18206

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Saxagliptin
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]